Publications
Detailed Information
Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Tae Won | - |
dc.contributor.author | Ryu, Min-Hee | - |
dc.contributor.author | Lee, Heungnam | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.contributor.author | Lee, Jae-Lyun | - |
dc.contributor.author | Chang, Heung Moon | - |
dc.contributor.author | Park, Young Suk | - |
dc.contributor.author | Lee, Kyung Hee | - |
dc.contributor.author | Kang, Won Ki | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Lee, Jung Shin | - |
dc.contributor.author | Kang, Yoon-Koo | - |
dc.date.accessioned | 2012-05-24T01:21:32Z | - |
dc.date.available | 2012-05-24T01:21:32Z | - |
dc.date.created | 2020-12-21 | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | Oncologist, Vol.14 No.5, pp.540-547 | - |
dc.identifier.issn | 1083-7159 | - |
dc.identifier.other | 119287 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76375 | - |
dc.description.abstract | Purpose. This study analyzed the relationship between treatment outcome and kinase mutational status in Korean patients with advanced gastrointestinal stromal tumors (GISTs). Experimental Design. Clinical data were collected from 113 consecutive patients with metastatic or unresectable GISTs treated with imatinib from June 2001 through June 2005 at five institutions in Korea. KIT exons 9, 11, 13, and 17 and PDGFRA exons 12 and 18 were examined. Results. The median patient age was 57 years (range, 31-82 years). The overall response rate was 67.2%. KIT mutations were found in exon 11 (n = 92, 81.4%) and exon 9 (n = 10, 8.8%). One patient had a PDGFRA exon 18 mutation. The overall mutation rate was 91.2%. Response rates were 68.4%, 50.0%, and 80.0% in patients with KIT exon 11 mutations, KIT exon 9 mutations, and no kinase mutations, respectively. With a median follow-up of 49.0 months, the median progression-free survival (PFS) time was 42.0 months and median overall survival (OS) time was not reached. PFS and OS times did not differ significantly according to KIT genotype. Conclusion. This study was unable to find an association between KIT mutational status and clinical outcome of imatinib in Korean patients with advanced GISTs. There was a trend toward better outcomes for patients with wild-type KIT or exon 11 mutations compared with exon 9 mutations, although this was not statistically significant. Compared with previous studies in western populations, these results suggest that ethnic differences may influence the relationship between KIT genotype and clinical outcome to imatinib. The Oncologist 2009;14:540-547 | - |
dc.language | 영어 | - |
dc.language.iso | en | ko_KR |
dc.publisher | AlphaMed Press Inc | - |
dc.title | Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1634/theoncologist.2008-0145 | - |
dc.citation.journaltitle | Oncologist | - |
dc.description.citedreference | Heinrich MC, 2008, J CLIN ONCOL, V26, P5352, DOI 10.1200/JCO.2007.15.7461 | - |
dc.description.citedreference | Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403 | - |
dc.description.citedreference | Blanke CD, 2008, J CLIN ONCOL, V26, P626, DOI 10.1200/JCO.2007.13.4452 | - |
dc.description.citedreference | McAuliffe JC, 2007, CLIN CANCER RES, V13, P6727, DOI 10.1158/1078-0432.CCR-07-0895 | - |
dc.description.citedreference | Choi H, 2007, J CLIN ONCOL, V25, P1753, DOI 10.1200/JCO.2006.07.3049 | - |
dc.description.citedreference | Benjamin RS, 2007, J CLIN ONCOL, V25, P1760, DOI 10.1200/JCO.2006.07.3411 | - |
dc.description.citedreference | Picard S, 2007, BLOOD, V109, P3496, DOI 10.1182/blood-2006-07-036012 | - |
dc.description.citedreference | Yeh CN, 2007, ANN SURG ONCOL, V14, P1123, DOI 10.1245/s10434-006-9288-1 | - |
dc.description.citedreference | VANGLABBEKE M, 2007, 2007 AM SOC CLIN ONC | - |
dc.description.citedreference | Widmer N, 2006, BRIT J CLIN PHARMACO, V62, P97, DOI 10.1111/j.1365-2125.2006.02719.x | - |
dc.description.citedreference | Debiec-Rychter M, 2006, EUR J CANCER, V42, P1093, DOI 10.1016/j.ejca.2006.01.030 | - |
dc.description.citedreference | Steinert DM, 2006, CANCER, V106, P1617, DOI 10.1002/cncr.21781 | - |
dc.description.citedreference | Ryu MH, 2006, JPN J CLIN ONCOL, V36, P17, DOI 10.1093/jjcol/hyi212 | - |
dc.description.citedreference | Hartmann K, 2005, GASTROENTEROLOGY, V129, P1042, DOI 10.1053/j.gastro.2005.06.060 | - |
dc.description.citedreference | Corless CL, 2005, J CLIN ONCOL, V23, P5357, DOI 10.1200/JCO.2005.14.068 | - |
dc.description.citedreference | Judson I, 2005, CANCER CHEMOTH PHARM, V55, P379, DOI 10.1007/s00280-004-0876-0 | - |
dc.description.citedreference | DILEO P, 2005, J CLIN ONCOL S16, V23, P9032 | - |
dc.description.citedreference | Sakurai S, 2004, HUM PATHOL, V35, P1223, DOI 10.1016/j.humpath.2004.07.008 | - |
dc.description.citedreference | Verweij J, 2004, LANCET, V364, P1127 | - |
dc.description.citedreference | Kim TW, 2004, CLIN CANCER RES, V10, P3076 | - |
dc.description.citedreference | Debiec-Rychter M, 2004, J PATHOL, V202, P430, DOI 10.1002/path.1546 | - |
dc.description.citedreference | Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190 | - |
dc.description.citedreference | Verweij J, 2003, EUR J CANCER, V39, P2006, DOI 10.1016/S0959-8049(02)00836-5 | - |
dc.description.citedreference | Demetri GD, 2002, NEW ENGL J MED, V347, P472 | - |
dc.description.citedreference | Andersson J, 2002, AM J PATHOL, V160, P15 | - |
dc.description.citedreference | Rubin BP, 2001, CANCER RES, V61, P8118 | - |
dc.description.citedreference | van Oosterom AT, 2001, LANCET, V358, P1421 | - |
dc.description.citedreference | Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139 | - |
dc.description.citedreference | Therasse P, 2000, J NATL CANCER I, V92, P205 | - |
dc.description.citedreference | Hirota S, 1998, SCIENCE, V279, P577 | - |
dc.description.citedreference | GREEN S, 1992, INVEST NEW DRUG, V10, P239 | - |
dc.description.tc | 3 | - |
dc.identifier.wosid | 000266293600010 | - |
dc.identifier.scopusid | 2-s2.0-66349110922 | - |
dc.citation.endpage | 547 | - |
dc.citation.number | 5 | - |
dc.citation.startpage | 540 | - |
dc.citation.volume | 14 | - |
dc.identifier.sci | 000266293600010 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | PROGRESSION-FREE SURVIVAL | - |
dc.subject.keywordPlus | BONE SARCOMA GROUP | - |
dc.subject.keywordPlus | EORTC SOFT-TISSUE | - |
dc.subject.keywordPlus | DOSE IMATINIB | - |
dc.subject.keywordPlus | C-KIT | - |
dc.subject.keywordPlus | RESPONSE CRITERIA | - |
dc.subject.keywordPlus | TYROSINE KINASE | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | MESYLATE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Imatinib | - |
dc.subject.keywordAuthor | Gastrointestinal stromal tumor | - |
dc.subject.keywordAuthor | KIT mutation | - |
dc.subject.keywordAuthor | PDGFRA mutation | - |
dc.subject.keywordAuthor | Korean | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.